

# Elisabeth G E De Vries

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6678143/publications.pdf>

Version: 2024-02-01

452  
papers

38,829  
citations

4960

84  
h-index

3650

180  
g-index

454  
all docs

454  
docs citations

454  
times ranked

45479  
citing authors

#	ARTICLE	IF	CITATIONS
1	Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. <i>European Journal of Cancer</i> , 2022, 160, 261-272.	2.8	7
2	Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. <i>Nature Medicine</i> , 2022, 28, 535-544.	30.7	158
3	COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 385-401.	27.6	135
4	Noise sensitivity of <sup>89</sup> Zr-Immuno-PET radiomics based on count-reduced clinical images. <i>EJNMMI Physics</i> , 2022, 9, 16.	2.7	3
5	<sup>89</sup> Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted <sup>227</sup> Th-conjugate therapy in mice. <i>Journal of Nuclear Medicine</i> , 2022, , jnumed.121.263079.	5.0	2
6	<sup>89</sup> Zr-PET imaging to predict tumor uptake of <sup>177</sup> Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma. <i>Scientific Reports</i> , 2022, 12, 6286.	3.3	3
7	Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours. <i>Lancet Oncology</i> , The, 2022, 23, 833-835.	10.7	18
8	The gut wall's potential as a partner for precision oncology in immune checkpoint treatment. <i>Cancer Treatment Reviews</i> , 2022, 107, 102406.	7.7	2
9	Clinical Validity of <sup>18</sup> F-Fluoro- <sup>17</sup> β-Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 3642-3652.	1.6	21
10	Predictive value of ectopic <i>HORMAD1</i> tumor expression for high-dose platinum-based chemotherapy benefit in patients with high-risk HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 541-541.	1.6	0
11	Defining Essential Childhood Cancer Medicines to Inform Prioritization and Access: Results From an International, Cross-Sectional Survey. <i>JCO Global Oncology</i> , 2022, , .	1.8	2
12	PET/CT Imaging of <sup>89</sup> Zr-N-sucDf-Pembrolizumab in Healthy Cynomolgus Monkeys. <i>Molecular Imaging and Biology</i> , 2021, 23, 250-259.	2.6	18
13	Assessment of Bone Lesions with <sup>18</sup> F-FDG PET Compared with <sup>99m</sup> Tc Bone Scintigraphy Leads to Clinically Relevant Differences in Metastatic Breast Cancer Management. <i>Journal of Nuclear Medicine</i> , 2021, 62, 177-183.	5.0	12
14	COVID-19 vaccination: the VOICE for patients with cancer. <i>Nature Medicine</i> , 2021, 27, 568-569.	30.7	53
15	Improving gene function predictions using independent transcriptional components. <i>Nature Communications</i> , 2021, 12, 1464.	12.8	20
16	Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.120.259036.	5.0	3
17	Current Treatment Strategies and Future Directions for Extrapulmonary Neuroendocrine Carcinomas. <i>JAMA Oncology</i> , 2021, 7, 759.	7.1	18
18	Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4369-4376.	6.4	23

#	ARTICLE	IF	CITATIONS
19	Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors. International Journal of Cancer, 2021, 149, 1455-1462.	5.1	16
20	CX-072 (pacmilimab), a Probody <sup>®</sup> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study. , 2021, 9, e002447.		26
21	The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. European Journal of Cancer, 2021, 151, 72-83.	2.8	12
22	First-in-Human Study of the Biodistribution and Pharmacokinetics of <sup>89</sup> Zr-CX-072, a Novel Immunopet Tracer Based on an Anti- <sup>®</sup> PD-L1 Probody. Clinical Cancer Research, 2021, 27, 5325-5333.	7.0	19
23	Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study. Blood Advances, 2021, 5, 2958-2964.	5.2	11
24	Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Lancet Oncology, The, 2021, 22, 1367-1377.	10.7	69
25	Mass spectrometric quantification of urinary 6-sulfatoxymelatonin: age-dependent excretion and biological variation. Clinical Chemistry and Laboratory Medicine, 2021, 59, 187-195.	2.3	2
26	Analyzing the Estrogen Receptor Status of Liver Metastases with [18F]-FES-PET in Patients with Breast Cancer. Diagnostics, 2021, 11, 2019.	2.6	4
27	mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncology, The, 2021, 22, 1681-1691.	10.7	118
28	Radiolabeled Monoclonal Antibody Against Colony-Stimulating Factor 1 Receptor Specifically Distributes to the Spleen and Liver in Immunocompetent Mice. Frontiers in Oncology, 2021, 11, 786191.	2.8	3
29	Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1. Oncogene, 2020, 39, 187-203.	5.9	34
30	Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers. Pathology and Oncology Research, 2020, 26, 1539-1547.	1.9	35
31	Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1. ESMO Open, 2020, 5, e000681.	4.5	5
32	A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging. Breast Cancer Research, 2020, 22, 97.	5.0	27
33	<sup>89</sup> Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs. , 2020, 8, e000938.		34
34	Visualizing Cancer. Cancer Cell, 2020, 38, 753-756.	16.8	4
35	Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. European Journal of Cancer, 2020, 141, 171-184.	2.8	65
36	Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies. ESMO Open, 2020, 5, e000743.	4.5	7

#	ARTICLE	IF	CITATIONS
37	Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer <sup>18</sup> F-BMS-986192. Journal of Nuclear Medicine, 2020, 61, 1839-1844.	5.0	37
38	Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1-Expressing Tumors Compared to Normal Murine Lymphoid Tissue. Clinical Cancer Research, 2020, 26, 3999-4009.	7.0	35
39	Molecular imaging in lymphoma beyond 18F-FDG-PET: understanding the biology and its implications for diagnostics and therapy. Lancet Haematology, 2020, 7, e479-e489.	4.6	14
40	Reconsider radiation exposure from imaging during immune checkpoint inhibitor trials to reduce risk of secondary cancers in long-term survivors?. Cancer Treatment Reviews, 2020, 87, 102027.	7.7	2
41	The global imperative to make cancer medications affordable. Lancet Oncology, The, 2020, 21, 609-610.	10.7	2
42	High hepatocyte growth factor expression in primary tumor predicts better overall survival in male breast cancer. Breast Cancer Research, 2020, 22, 30.	5.0	7
43	Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT). Clinical Cancer Research, 2020, 26, 2461-2465.	7.0	6
44	Development and Evaluation of Interleukin-2-Derived Radiotracers for PET Imaging of T Cells in Mice. Journal of Nuclear Medicine, 2020, 61, 1355-1360.	5.0	32
45	Which patients are prone to undergo disproportionate recurrent CT imaging and should we worry?. European Journal of Radiology, 2020, 125, 108898.	2.6	10
46	High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes. JAMA Oncology, 2020, 6, 528.	7.1	17
47	Neuroendocrine tumours and their microenvironment. Cancer Immunology, Immunotherapy, 2020, 69, 1449-1459.	4.2	13
48	EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. ESMO Open, 2020, 5, e000611.	4.5	10
49	The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 Arm. Journal of Nuclear Medicine, 2020, 61, 1594-1601.	5.0	9
50	Measuring Clinical Benefit of Treatments for Hematologic Malignancies: Critical First Steps Accomplished-What is Next?. HemaSphere, 2020, 4, e354.	2.7	0
51	Transcriptional effects of copy number alterations in a large set of human cancers. Nature Communications, 2020, 11, 715.	12.8	53
52	Visual and quantitative evaluation of [18F]FES and [18F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study. EJNMMI Research, 2020, 10, 40.	2.5	13
53	Fluorescent image-guided surgery in breast cancer by intravenous application of a quenched fluorescence activity-based probe for cysteine cathepsins in a syngeneic mouse model. EJNMMI Research, 2020, 10, 111.	2.5	24
54	Prediction of watchful waiting in newly diagnosed metastatic clear cell renal cell carcinoma patients with a good or intermediate prognosis.. Journal of Clinical Oncology, 2020, 38, 5079-5079.	1.6	1

#	ARTICLE	IF	CITATIONS
55	PROCLAIM-CX-072: Analysis of patients with advanced solid tumors receiving long-term treatment with CX-072, a PD-L1 probody therapeutic, as a single agent or in combination with ipilimumab.. Journal of Clinical Oncology, 2020, 38, 3005-3005.	1.6	1
56	Sulfonylurea derivatives and cancer, friend or foe?. European Journal of Pharmacology, 2019, 861, 172598.	3.5	25
57	<i><scp>RAS</scp></i> and <i><scp>BRAF</scp></i> mutations in cellâ€free <scp>DNA</scp> are predictive for outcome of cetuximab monotherapy in patients with tissueâ€tested <i><scp>RAS</scp></i> wildâ€type advanced colorectal cancer. Molecular Oncology, 2019, 13, 2361-2374.	4.6	32
58	Correcting the Conclusion in a Study of Frameworks for Measurement of Absolute or Relative Clinical Survival Benefit. JAMA Oncology, 2019, 5, 1807.	7.1	1
59	When is off-label off-road?. Annals of Oncology, 2019, 30, 1536-1538.	1.2	12
60	Modeling of Cisplatin-Induced Signaling Dynamics in Triple-Negative Breast Cancer Cells Reveals Mediators of Sensitivity. Cell Reports, 2019, 28, 2345-2357.e5.	6.4	25
61	Clinical-grade N-(4-[18F]fluorobenzoyl)-interleukin-2 for PET imaging of activated T-cells in humans. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 15.	3.9	15
62	Melatonin is not stored in platelets. Clinica Chimica Acta, 2019, 498, 17-20.	1.1	3
63	Quantitative Profiling of Platelet-Rich Plasma Indole Markers by Direct-Matrix Derivatization Combined with LC-MS/MS in Patients with Neuroendocrine Tumors. Clinical Chemistry, 2019, 65, 1388-1396.	3.2	16
64	Interobserver reproducibility of tumor uptake quantification with 89Zr-immuno-PET: a multicenter analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1840-1849.	6.4	11
65	Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncology, The, 2019, 20, 1124-1135.	10.7	339
66	Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1931-1939.	6.4	53
67	Consideration of breast cancer subtype in targeting the androgen receptor. , 2019, 200, 135-147.		65
68	Shortages of inexpensive essential medicines. Lancet Oncology, The, 2019, 20, e224-e225.	10.7	4
69	A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. , 2019, 201, 103-119.		194
70	Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology. ESMO Open, 2019, 4, e000460.	4.5	39
71	A large pooled analysis refines gene expression-based molecular subclasses in cutaneous melanoma. Oncoimmunology, 2019, 8, 1558664.	4.6	0
72	RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis. Journal of Clinical Oncology, 2019, 37, 1102-1110.	1.6	53

#	ARTICLE	IF	CITATIONS
73	Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. Journal of Clinical Oncology, 2019, 37, 336-349.	1.6	101
74	ESMO-MCBS: setting the record straight. Lancet Oncology, The, 2019, 20, e192.	10.7	2
75	89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake. Clinical Cancer Research, 2019, 25, 3517-3527.	7.0	34
76	89Zr-labeled anti-PD-L1 CX-072 PET imaging in human xenograft and syngeneic tumors. Annals of Oncology, 2019, 30, i4.	1.2	7
77	A Conversation Between Elisabeth de Vries and Johannes Czernin. Journal of Nuclear Medicine, 2019, 60, 1337-1339.	5.0	1
78	Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response. Immuno-Oncology Technology, 2019, 4, 1-7.	0.3	2
79	Encouraging AWARe-ness and discouraging inappropriate antibiotic use—the new 2019 Essential Medicines List becomes a global antibiotic stewardship tool. Lancet Infectious Diseases, The, 2019, 19, 1278-1280.	9.1	106
80	Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT. Clinical Nuclear Medicine, 2019, 44, 612-619.	1.3	3
81	Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results. American Journal of Surgical Pathology, 2019, 43, 1355-1360.	3.7	20
82	Integrating molecular nuclear imaging in clinical research to improve anticancer therapy. Nature Reviews Clinical Oncology, 2019, 16, 241-255.	27.6	56
83	Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition. Oncogene, 2019, 38, 1477-1488.	5.9	11
84	Letter to the Editor: When Expertly Applied, ESMO-MCBS and ASCO Net Health Benefit Scores Usually Agree. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, xxi.	4.9	1
85	Reply to the letter to the editor “ESMO-MCBS v1.1: statistical and patient relevant shortcomings” by Emrechtinger et al.. Annals of Oncology, 2018, 29, 1335-1338.	1.2	0
86	Reply to the letter to the editor “Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies”. Annals of Oncology, 2018, 29, 774-775.	1.2	1
87	Influence of protein properties and protein modification on biodistribution and tumor uptake of anticancer antibodies, antibody derivatives, and non-igg scaffolds. Medicinal Research Reviews, 2018, 38, 1837-1873.	10.5	12
88	Use of Video-consultation is Feasible During Follow-up Care of Patients with a Neuroendocrine Tumour. Clinical Oncology, 2018, 30, 396.	1.4	2
89	Reply to the letter to the editor “Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?” by Del Paggio. Annals of Oncology, 2018, 29, 521-522.	1.2	1
90	Towards optimal personalized diet and vitamin supplementation in NET patients. Endocrine-Related Cancer, 2018, 25, L23-L26.	3.1	4

#	ARTICLE	IF	CITATIONS
91	Molecular Imaging in Cancer Drug Development. Journal of Nuclear Medicine, 2018, 59, 726-732.	5.0	50
92	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncology, The, 2018, 19, e20-e32.	10.7	87
93	<sup>18</sup> F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients. Journal of Nuclear Medicine, 2018, 59, 1212-1218.	5.0	45
94	RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. Journal of the National Cancer Institute, 2018, 110, 1142-1143.	6.3	1
95	Evolution in sentinel lymph node biopsy in breast cancer. Critical Reviews in Oncology/Hematology, 2018, 123, 83-94.	4.4	67
96	Immune Modulation Therapy and Imaging: Workshop Report. Journal of Nuclear Medicine, 2018, 59, 410-417.	5.0	23
97	Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative 18F-FDG PET/CT analysis. EJNMMI Research, 2018, 8, 101.	2.5	18
98	89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nature Medicine, 2018, 24, 1852-1858.	30.7	468
99	European Academy of Cancer Sciences " position paper. Molecular Oncology, 2018, 12, 1829-1837.	4.6	9
100	Molecular imaging to enlighten cancer immunotherapies and underlying involved processes. Cancer Treatment Reviews, 2018, 70, 232-244.	7.7	36
101	Comparative biodistribution analysis across four different <sup>89</sup> Zr-monoclonal antibody tracers" The first step towards an imaging warehouse. Theranostics, 2018, 8, 4295-4304.	10.0	46
102	Tumor-associated macrophages in breast cancer: Innocent bystander or important player?. Cancer Treatment Reviews, 2018, 70, 178-189.	7.7	305
103	Preparing for the incoming wave of biosimilars in oncology. ESMO Open, 2018, 3, e000420.	4.5	8
104	Androgen receptor expression inversely correlates with immune cell infiltration in human epidermal growth factor receptor 2"positive breast cancer. European Journal of Cancer, 2018, 103, 52-60.	2.8	16
105	Glypican 3 Overexpression across a Broad Spectrum of Tumor Types Discovered with Functional Genomic mRNA Profiling of a Large Cancer Database. American Journal of Pathology, 2018, 188, 1973-1981.	3.8	30
106	Potential Red-Flag Identification of Colorectal Adenomas with Wide-Field Fluorescence Molecular Endoscopy. Theranostics, 2018, 8, 1458-1467.	10.0	49
107	Micro-computed tomography (micro-CT) for intraoperative surgical margin assessment of breast cancer: A feasibility study in breast conserving surgery. European Journal of Surgical Oncology, 2018, 44, 1708-1713.	1.0	32
108	Molecular Imaging of Radiolabeled Bispecific T-Cell Engager 89Zr-AMG211 Targeting CEA-Positive Tumors. Clinical Cancer Research, 2018, 24, 4988-4996.	7.0	23



#	ARTICLE	IF	CITATIONS
109	Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2404-2412.	6.4	21
110	Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework. <i>JAMA Oncology</i> , 2018, 4, 1437.	7.1	1
111	Considering the biology of late recurrences in selecting patients for extended endocrine therapy in breast cancer. <i>Cancer Treatment Reviews</i> , 2018, 70, 118-126.	7.7	13
112	<sup>89</sup> Zr-Bevacizumab PET: Potential Early Indicator of Everolimus Efficacy in Patients with Metastatic Renal Cell Carcinoma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 905-910.	5.0	50
113	Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study. <i>Clinical Cancer Research</i> , 2017, 23, 2730-2741.	7.0	212
114	iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. <i>Lancet Oncology</i> , The, 2017, 18, e143-e152.	10.7	1,612
115	Synthesis and Evaluation of the Estrogen Receptor <sup>125</sup> I-Selective Radioligand 2- <sup>18</sup> F-Fluoro-6-(6-Hydroxynaphthalen-2-yl)Pyridin-3-ol: Comparison with 16 $\alpha$ - <sup>18</sup> F-Fluoro-17 $\beta$ -Estradiol. <i>Journal of Nuclear Medicine</i> , 2017, 58, 554-559.	5.0	19
116	Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2017, 46, 751-757.	1.1	6
117	Human Epidermal Growth Factor Receptor 3-Specific Tumor Uptake and Biodistribution of <sup>89</sup> Zr-MSB0010853 Visualized by Real-Time and Noninvasive PET Imaging. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1210-1215.	5.0	39
118	<sup>89</sup> Zr-Onartuzumab PET imaging of c-MET receptor dynamics. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1328-1336.	6.4	26
119	RECIST – learning from the past to build the future. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 187-192.	27.6	78
120	The antibody-drug conjugate target landscape across a broad range of tumour types. <i>Annals of Oncology</i> , 2017, 28, 3083-3091.	1.2	40
121	ESMO-Magnitude of Clinical Benefit Scale version 1.1. <i>Annals of Oncology</i> , 2017, 28, 2340-2366.	1.2	451
122	Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1906-1912.	5.0	48
123	Theranostics Using Antibodies and Antibody-Related Therapeutics. <i>Journal of Nuclear Medicine</i> , 2017, 58, 83S-90S.	5.0	85
124	<sup>89</sup> Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment. <i>MAbs</i> , 2017, 9, 1370-1378.	5.2	20
125	Web-Based Tailored Psychoeducation for Breast Cancer Patients at the Onset of the Survivorship Phase: A Multicenter Randomized Controlled Trial. <i>Journal of Pain and Symptom Management</i> , 2017, 54, 466-475.	1.2	43
126	<sup>89</sup> Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 6128-6137.	7.0	51



#	ARTICLE	IF	CITATIONS
127	In Vivo Quantification of ER <sup>12</sup> Expression by Pharmacokinetic Modeling: Studies with <sup>18</sup> F-FHNP PET. Journal of Nuclear Medicine, 2017, 58, 1743-1748.	5.0	6
128	Reply to the letter to the editor ~Addressing the quality of the ESMO-MCBS™ by Del Paggio. Annals of Oncology, 2017, 28, 2031-2032.	1.2	0
129	Pancreatic Uptake by 18F-FDOPA PET/CT in Patients With Hypoglycemia After Gastric Bypass Surgery Compared With Controls With or Without Carbidopa Pretreatment. Clinical Nuclear Medicine, 2017, 42, 163-168.	1.3	3
130	20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. New England Journal of Medicine, 2017, 377, 1836-1846.	27.0	1,052
131	Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer. Journal of the National Cancer Institute, 2017, 109, djw192.	6.3	296
132	Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer. Cancer Research, 2017, 77, 623-631.	0.9	34
133	Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules. ESMO Open, 2017, 2, e000216.	4.5	20
134	Indispensable benefit of independent investigator-driven research in a changing clinical trial landscape. ESMO Open, 2017, 2, e000272.	4.5	2
135	Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine. Theranostics, 2017, 7, 2111-2133.	10.0	12
136	ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells. Oncotarget, 2017, 8, 45432-45446.	1.8	23
137	Molecular Imaging in Head and Neck Squamous Cell Carcinoma Patients. , 2017, , 77-96.		1
138	Validation of RECIST 1.1 for use with cytotoxic agents and targeted cancer agents (TCA): Results of a RECIST Working Group analysis of a 50 clinical trials pooled individual patient database.. Journal of Clinical Oncology, 2017, 35, 2534-2534.	1.6	7
139	Pharmacokinetics of cetuximab and tumor uptake of <sup>89</sup> Zr-cetuximab as potential predictive biomarkers for benefit of cetuximab in patients with advanced colorectal cancer.. Journal of Clinical Oncology, 2017, 35, e15117-e15117.	1.6	2
140	Change in metabolic tumor activity on <sup>18</sup> F-FDG PET after a single dose of cetuximab to predict for treatment benefit, PFS, and OS in patients with advanced colorectal cancer.. Journal of Clinical Oncology, 2017, 35, 11519-11519.	1.6	0
141	Emerging Opportunities for c-MET Visualization in the Clinic. Journal of Nuclear Medicine, 2016, 57, 663-664.	5.0	4
142	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 2016, 1, e000097.	4.5	82
143	Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma. Cancer Treatment Reviews, 2016, 46, 63-72.	7.7	16
144	RECIST 1.1~Update and clarification: From the RECIST committee. European Journal of Cancer, 2016, 62, 132-137.	2.8	1,143

#	ARTICLE	IF	CITATIONS
145	Development, preclinical safety, formulation, and stability of clinical grade bevacizumab-800CW, a new near infrared fluorescent imaging agent for first in human use. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2016, 104, 226-234.	4.3	47
146	Bleomycin-Induced Pulmonary Changes on Restaging Computed Tomography Scans in Two Thirds of Testicular Cancer Patients Show No Correlation With Fibrosis Markers. <i>Oncologist</i> , 2016, 21, 995-1001.	3.7	9
147	Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 3906-3913.	1.6	206
148	<sup>89</sup> Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1244-1250.	5.0	17
149	Difference in CXCR4 expression between sporadic and VHL-related hemangioblastoma. <i>Familial Cancer</i> , 2016, 15, 607-616.	1.9	11
150	RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. <i>European Journal of Cancer</i> , 2016, 62, 138-145.	2.8	211
151	Potential value of EUS in pancreatic surveillance of VHL patients. <i>European Journal of Endocrinology</i> , 2016, 174, 611-620.	3.7	10
152	Angiotensin II Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 1030.	7.1	160
153	ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment. <i>Clinical Cancer Research</i> , 2016, 22, 1642-1652.	7.0	74
154	Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation. <i>Journal of Nuclear Medicine</i> , 2016, 57, 96S-104S.	5.0	8
155	Biodistribution and PET Imaging of Labeled Bispecific T Cell-Engaging Antibody Targeting EpCAM. <i>Journal of Nuclear Medicine</i> , 2016, 57, 812-817.	5.0	31
156	Imaging Diagnostic and Therapeutic Targets: Human Epidermal Growth Factor Receptor 2. <i>Journal of Nuclear Medicine</i> , 2016, 57, 81S-88S.	5.0	43
157	Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 439-447.	4.1	85
158	Breaking the DNA damage response to improve cervical cancer treatment. <i>Cancer Treatment Reviews</i> , 2016, 42, 30-40.	7.7	54
159	Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. <i>Annals of Oncology</i> , 2016, 27, 619-624.	1.2	269
160	Niacin (Vitamin B <sub>3</sub> ) Supplementation in Patients with Serotonin-Producing Neuroendocrine Tumor. <i>Neuroendocrinology</i> , 2016, 103, 489-494.	2.5	39
161	Androgen receptor and estrogen receptor imaging in patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11553-11553.	1.6	2
162	A Phase 1 study of RAD1901, an oral selective estrogen receptor degrader, in ER positive, HER2 negative, advanced breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS627-TPS627.	1.6	2

#	ARTICLE	IF	CITATIONS
163	Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imagatuzumab. <i>Oncotarget</i> , 2016, 7, 68111-68121.	1.8	16
164	VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. <i>Oncotarget</i> , 2016, 7, 21247-21258.	1.8	86
165	89Zr-lumretuzumab PET imaging before and during HER3 antibody lumretuzumab treatment of solid tumor patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11555-11555.	1.6	0
166	Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with 89Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts. <i>Oncotarget</i> , 2015, 6, 42081-42090.	1.8	31
167	Microenvironment involved in FPR1 expression by human glioblastomas. <i>Journal of Neuro-Oncology</i> , 2015, 123, 53-63.	2.9	9
168	Cancer-drug induced insulin resistance: Innocent bystander or unusual suspect. <i>Cancer Treatment Reviews</i> , 2015, 41, 376-384.	7.7	48
169	<sup>89</sup> Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment. <i>Journal of Nuclear Medicine</i> , 2015, 56, 63-69.	5.0	100
170	Assessment of Estrogen Receptor Expression in Epithelial Ovarian Cancer Patients Using <sup>16</sup> α- <sup>18</sup> F-Fluoro- <sup>17</sup> β-Estradiol PET/CT. <i>Journal of Nuclear Medicine</i> , 2015, 56, 50-55.	5.0	44
171	Antibody Positron Emission Tomography Imaging in Anticancer Drug Development. <i>Journal of Clinical Oncology</i> , 2015, 33, 1491-1504.	1.6	93
172	Response assessment criteria for brain metastases: proposal from the RANO group. <i>Lancet Oncology</i> , The, 2015, 16, e270-e278.	10.7	711
173	Vemurafenib-Induced Disseminated Intravascular Coagulation in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, e133-e134.	1.6	10
174	A Phase Ib Study of the VEGF Receptor Tyrosine Kinase Inhibitor Tivozanib and Modified FOLFOX-6 in Patients With Advanced Gastrointestinal Malignancies. <i>Clinical Colorectal Cancer</i> , 2015, 14, 18-24.e1.	2.3	10
175	Gene expression analysis identifies global gene dosage sensitivity in cancer. <i>Nature Genetics</i> , 2015, 47, 115-125.	21.4	313
176	Objective allergy markers and risk of cancer mortality and hospitalization in a large population-based cohort. <i>Cancer Causes and Control</i> , 2015, 26, 99-109.	1.8	12
177	Internet-based support programs to alleviate psychosocial and physical symptoms in cancer patients: A literature analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 26-37.	4.4	81
178	The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients. <i>British Journal of Cancer</i> , 2015, 112, 1617-1625.	6.4	18
179	Regulators of homologous recombination repair as novel targets for cancer treatment. <i>Frontiers in Genetics</i> , 2015, 6, 96.	2.3	58
180	Rectal and colon cancer: Not just a different anatomic site. <i>Cancer Treatment Reviews</i> , 2015, 41, 671-679.	7.7	239

#	ARTICLE	IF	CITATIONS
181	Immunotherapeutic options on the horizon in breast cancer treatment. , 2015, 156, 90-101.		17
182	Hormone receptors as a marker of poor survival in epithelial ovarian cancer. Gynecologic Oncology, 2015, 138, 634-639.	1.4	43
183	Molecular Imaging As a Tool for Drug Development and Trial Design. Journal of Clinical Oncology, 2015, 33, 2585-2587.	1.6	27
184	TGF- $\beta^2$ Antibody Uptake in Recurrent High-Grade Glioma Imaged with <sup>89</sup> Zr-Fresolimumab PET. Journal of Nuclear Medicine, 2015, 56, 1310-1314.	5.0	78
185	Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors. Annals of Oncology, 2015, 26, 2305-2310.	1.2	61
186	Positron emission tomography of tumour [18F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1674-1681.	6.4	48
187	A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Annals of Oncology, 2015, 26, 1547-1573.	1.2	635
188	Rif1 Is Required for Resolution of Ultrafine DNA Bridges in Anaphase to Ensure Genomic Stability. Developmental Cell, 2015, 34, 466-474.	7.0	74
189	EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1. Gastrointestinal Endoscopy, 2015, 81, 159-167.e2.	1.0	69
190	Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer. Cancer Discovery, 2015, 5, 72-81.	9.4	168
191	ATR inhibition preferentially targets homologous recombination-deficient tumor cells. Oncogene, 2015, 34, 3474-3481.	5.9	80
192	Everolimus in patients with advanced, progressive pancreatic neuroendocrine tumors: Overall survival results from the phase III RADIANT-3 study after adjusting for crossover bias.. Journal of Clinical Oncology, 2015, 33, 4091-4091.	1.6	5
193	FES PET/CT analysis to evaluate the impact of localization of breast cancer metastases on ER expression.. Journal of Clinical Oncology, 2015, 33, 527-527.	1.6	2
194	Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion for relapsed/refractory gastrointestinal (GI) adenocarcinoma.. Journal of Clinical Oncology, 2015, 33, TPS3097-TPS3097.	1.6	3
195	Growth Differentiation Factor 15 (GDF-15) Plasma Levels Increase during Bleomycin- and Cisplatin-Based Treatment of Testicular Cancer Patients and Relate to Endothelial Damage. PLoS ONE, 2015, 10, e0115372.	2.5	37
196	Human stromal cells are required for an anti-breast cancer effect of zoledronic acid. Oncotarget, 2015, 6, 24436-24447.	1.8	6
197	Functional Genomic mRNA Profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types. Oncotarget, 2015, 6, 28164-28172.	1.8	22
198	CXCR4 and CXCL12 Expression in Rectal Tumors of Stage IV Patients Before and After Local Radiotherapy and Systemic Neoadjuvant Treatment. Current Pharmaceutical Design, 2015, 21, 2276-2283.	1.9	15

#	ARTICLE	IF	CITATIONS
199	Bleomycin-induced pulmonary changes on restaging CT scans: Frequency and correlation with fibrosis markers.. Journal of Clinical Oncology, 2015, 33, 4540-4540.	1.6	0
200	CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model. Clinical and Experimental Metastasis, 2014, 31, 829-839.	3.3	35
201	89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients. Clinical Cancer Research, 2014, 20, 3945-3954.	7.0	105
202	ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody<sup>89</sup>Zr-RG7116. MAbs, 2014, 6, 1051-1058.	5.2	46
203	Words Matter: Distinguishing "Personalized Medicine" and "Biologically Personalized Therapeutics". Journal of the National Cancer Institute, 2014, 106, dju321-dju321.	6.3	26
204	Dopamine and serotonin regulate tumor behavior by affecting angiogenesis. Drug Resistance Updates, 2014, 17, 96-104.	14.4	57
205	<scp>APC</scp>/<scp>C<sup>C</sup></scp><sup>dh1</sup> controls Ct<scp>IP</scp> stability during the cell cycle and in response to <scp>DNA</scp> damage. EMBO Journal, 2014, 33, 2860-2879.	7.8	65
206	Considerations on absence of 68Ga-DOTA-F(abâ€²)2-trastuzumab tracer uptake in HER2-overexpressing tumor lesions. Nuclear Medicine Communications, 2014, 35, 785-786.	1.1	1
207	Calculating optimal surveillance for detection of von Hippelâ€“Lindau-related manifestations. Endocrine-Related Cancer, 2014, 21, 63-71.	3.1	44
208	Video-rate optical flow corrected intraoperative functional fluorescence imaging. Journal of Biomedical Optics, 2014, 19, 1.	2.6	2
209	Dispelling the myths around cancer care delivery: It's not all about costs. Journal of Cancer Policy, 2014, 2, 22-29.	1.4	25
210	HER3, serious partner in crime. , 2014, 143, 1-11.		55
211	Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet, The, 2014, 383, 2127-2135.	13.7	1,701
212	Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Investigational New Drugs, 2014, 32, 135-144.	2.6	35
213	Everolimus Reduces <sup>89</sup>Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors. Journal of Nuclear Medicine, 2014, 55, 1087-1092.	5.0	56
214	Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Research, 2014, 16, R47.	5.0	86
215	In Vivo Visualization of MET Tumor Expression and Anticalin Biodistribution with the MET-Specific Anticalin <sup>89</sup>Zr-PRS-110 PET Tracer. Journal of Nuclear Medicine, 2014, 55, 665-671.	5.0	40
216	Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer. European Journal of Cancer, 2014, 50, 2508-2516.	2.8	15

#	ARTICLE	IF	CITATIONS
217	The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database. <i>European Journal of Cancer</i> , 2014, 50, 1847-1853.	2.8	32
218	<sup>111</sup> In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment. <i>Molecular Imaging</i> , 2014, 13, 7290.2014.00011.	1.4	39
219	PET/CT with <sup>89</sup> Zr-trastuzumab and <sup>18</sup> F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2-positive breast cancer (mBC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 11001-11001.	1.6	13
220	Phase I imaging study of the HER3 antibody RG7116 using <sup>89</sup> Zr-RG7116-PET in patients with metastatic or locally advanced HER3-positive solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11095-11095.	1.6	7
221	Prospective analysis of serial FLT-PET scanning to discriminate between true and pseudoprogression in glioblastoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2009-2009.	1.6	2
222	A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or platinum-resistant ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 2529-2529.	1.6	5
223	Residual estrogen receptor availability during fulvestrant 500 mg therapy in patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 588-588.	1.6	0
224	<sup>89</sup> Zr-bevacizumab PET imaging of disease manifestations in patients with Von Hippel-Lindau disease.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11090-11090.	1.6	0
225	Hemodialysis no reason to withhold everolimus. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 273-274.	2.3	5
226	Inhibition of formyl peptide receptor in high-grade astrocytoma by Chemotaxis Inhibitory Protein of <i>S. aureus</i> . <i>British Journal of Cancer</i> , 2013, 108, 587-596.	6.4	22
227	PET imaging of oestrogen receptors in patients with breast cancer. <i>Lancet Oncology</i> , The, 2013, 14, e465-e475.	10.7	173
228	A review on CXCR4/CXCL12 axis in oncology: No place to hide. <i>European Journal of Cancer</i> , 2013, 49, 219-230.	2.8	526
229	Targeting FLIP and Mcl-1 using a combination of aspirin and Sorafenib sensitizes colon cancer cells to TRAIL. <i>Journal of Pathology</i> , 2013, 229, 410-421.	4.5	28
230	Effect of vemurafenib on a V600R melanoma brain metastasis. <i>European Journal of Cancer</i> , 2013, 49, 1795-1796.	2.8	7
231	Translating TRAIL-receptor targeting agents to the clinic. <i>Cancer Letters</i> , 2013, 332, 194-201.	7.2	67
232	Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. <i>Oncogene</i> , 2013, 32, 3001-3008.	5.9	108
233	Molecular imaging for monitoring treatment response in breast cancer patients. <i>European Journal of Pharmacology</i> , 2013, 717, 2-11.	3.5	14
234	Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL. <i>British Journal of Cancer</i> , 2013, 109, 2685-2695.	6.4	35



#	ARTICLE	IF	CITATIONS
235	Bevacizumab-Induced Vessel Normalization Hampers Tumor Uptake of Antibodiesâ€”Response. Cancer Research, 2013, 73, 7147-7148.	0.9	11
236	Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake. Cancer Research, 2013, 73, 3347-3355.	0.9	103
237	<sup>89</sup> Zr-Bevacizumab PET Imaging in Primary Breast Cancer. Journal of Nuclear Medicine, 2013, 54, 1014-1018.	5.0	141
238	Placental Growth Factor (PlGF)â€™Specific Uptake in Tumor Microenvironment of <sup>89</sup> Zr-Labeled PlGF Antibody RO5323441. Journal of Nuclear Medicine, 2013, 54, 929-935.	5.0	16
239	Endothelial Damage in Long-Term Survivors of Childhood Cancer. Journal of Clinical Oncology, 2013, 31, 3906-3913.	1.6	52
240	HIF-1 $\pm$ Overexpression in Ductal Carcinoma In Situ of the Breast in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2013, 8, e56055.	2.5	32
241	<sup>89</sup> zr-GC1008 PET imaging and GC1008 treatment of recurrent glioma patients.. Journal of Clinical Oncology, 2013, 31, 2050-2050.	1.6	8
242	Zirconium-89-Trastuzumab Positron Emission Tomography As a Tool to Solve a Clinical Dilemma in a Patient With Breast Cancer. Journal of Clinical Oncology, 2012, 30, e74-e75.	1.6	32
243	Measurement of Tumor VEGF-A Levels with <sup>89</sup> Zr-Bevacizumab PET as an Early Biomarker for the Antiangiogenic Effect of Everolimus Treatment in an Ovarian Cancer Xenograft Model. Clinical Cancer Research, 2012, 18, 6306-6314.	7.0	56
244	Heterogeneity in simvastatin-induced cytotoxicity in AML is caused by differences in Ras-isoprenylation. Leukemia, 2012, 26, 845-848.	7.2	14
245	Human Papilloma Virus 16 E6 RNA Interference Enhances Cisplatin and Death Receptor-Mediated Apoptosis in Human Cervical Carcinoma Cells. Molecular Pharmacology, 2012, 81, 701-709.	2.3	36
246	PET Imaging of Estrogen Receptors as a Diagnostic Tool for Breast Cancer Patients Presenting with a Clinical Dilemma. Journal of Nuclear Medicine, 2012, 53, 182-190.	5.0	136
247	Multiple VEGF Family Members are Simultaneously Expressed in Ovarian Cancer: a Proposed Model for Bevacizumab Resistance. Current Pharmaceutical Design, 2012, 18, 3784-3792.	1.9	20
248	Lapatinib and 17AAG Reduce <sup>89</sup> Zr-Trastuzumab-F(ab $\epsilon^2$ ) <sub>2</sub> Uptake in SKBR3 Tumor Xenografts. Molecular Pharmaceutics, 2012, 9, 2995-3002.	4.6	40
249	Development of a radioiodinated apoptosisâ€”inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies. British Journal of Pharmacology, 2012, 165, 2203-2212.	5.4	16
250	Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer. Critical Reviews in Oncology/Hematology, 2012, 84, 224-242.	4.4	8
251	Pro- and anti-apoptotic effects of p53 in cisplatin-treated human testicular cancer are cell context-dependent. Cell Cycle, 2012, 11, 4552-4562.	2.6	30
252	CXCR4 Inhibition with AMD3100 Sensitizes Prostate Cancer to Docetaxel Chemotherapy. Neoplasia, 2012, 14, 709-718.	5.3	176



#	ARTICLE	IF	CITATIONS
253	The role of ATM and 53BP1 as predictive markers in cervical cancer. International Journal of Cancer, 2012, 131, 2056-2066.	5.1	35
254	Treatment with high-dose simvastatin inhibits geranylgeranylation in AML blast cells in a subset of AML patients. Experimental Hematology, 2012, 40, 177-186.e6.	0.4	15
255	Tailored imaging of islet cell tumors of the pancreas amidst increasing options. Critical Reviews in Oncology/Hematology, 2012, 82, 213-226.	4.4	9
256	Transforming growth factor (TGF)- $\beta$ 2 expression and activation mechanisms as potential targets for anti-tumor therapy and tumor imaging. , 2012, 135, 123-132.		35
257	89 Zr-bevacizumab PET imaging in metastatic renal cell carcinoma patients before and during antiangiogenic treatment.. Journal of Clinical Oncology, 2012, 30, 10581-10581.	1.6	10
258	The components of progression as explanatory variables for overall survival in the RECIST database.. Journal of Clinical Oncology, 2012, 30, 10602-10602.	1.6	0
259	Association of long-term exposure to circulating platinum with adverse late effects in testicular cancer survivors.. Journal of Clinical Oncology, 2012, 30, 4528-4528.	1.6	0
260	Macrophage inhibitory cytokine 1 plasma levels in testicular cancer patients during cisplatin combination treatment and their relation to endothelial damage.. Journal of Clinical Oncology, 2012, 30, e15035-e15035.	1.6	0
261	Everolimus for Advanced Pancreatic Neuroendocrine Tumors. New England Journal of Medicine, 2011, 364, 514-523.	27.0	2,547
262	VEGF-SPECT with 111In-bevacizumab in stage III/IV melanoma patients. European Journal of Cancer, 2011, 47, 1595-1602.	2.8	51
263	Systolic and diastolic dysfunction in long-term adult survivors of childhood cancer. European Journal of Cancer, 2011, 47, 2453-2462.	2.8	54
264	Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, The, 2011, 378, 771-784.	13.7	2,495
265	Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet, The, 2011, 378, 1707-1716.	13.7	3,080
266	Targeting Trail Towards the Clinic. Current Drug Targets, 2011, 12, 2079-2090.	2.1	21
267	A bioinformatical and functional approach to identify novel strategies for chemoprevention of colorectal cancer. Oncogene, 2011, 30, 2026-2036.	5.9	22
268	Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. British Journal of Cancer, 2011, 104, 1278-1287.	6.4	36
269	Perspectives for tailored chemoprevention and treatment of colorectal cancer in Lynch syndrome. Critical Reviews in Oncology/Hematology, 2011, 80, 264-277.	4.4	11
270	Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1854-1861.	6.4	41

#	ARTICLE	IF	CITATIONS
271	TNF-related apoptosis-inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cells. <i>Journal of Pathology</i> , 2011, 223, 378-389.	4.5	10
272	Current status and future developments of LC-MS/MS in clinical chemistry for quantification of biogenic amines. <i>Clinical Biochemistry</i> , 2011, 44, 95-103.	1.9	66
273	The chemokine network, a newly discovered target in high grade gliomas. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 79, 154-163.	4.4	27
274	Intraoperative Near-Infrared Fluorescence Tumor Imaging with Vascular Endothelial Growth Factor and Human Epidermal Growth Factor Receptor 2 Targeting Antibodies. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1778-1785.	5.0	186
275	PET with the <sup>89</sup> Zr-Labeled Transforming Growth Factor- $\beta$ Antibody Fresolimumab in Tumor Models. <i>Journal of Nuclear Medicine</i> , 2011, 52, 2001-2008.	5.0	51
276	Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer. <i>Annals of Oncology</i> , 2011, 22, 2286-2293.	1.2	41
277	Toward Molecular Imaging-Driven Drug Development in Oncology. <i>Cancer Discovery</i> , 2011, 1, 25-28.	9.4	21
278	Everolimus Induces Rapid Plasma Glucose Normalization in Insulinoma Patients by Effects on Tumor As Well As Normal Tissues. <i>Oncologist</i> , 2011, 16, 783-787.	3.7	62
279	High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials. <i>Journal of Clinical Oncology</i> , 2011, 29, 3214-3223.	1.6	89
280	VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment. <i>Cancer Research</i> , 2011, 71, 143-153.	0.9	105
281	Involvement of the TGF- $\beta$ and $\beta$ -Catenin Pathways in Pelvic Lymph Node Metastasis in Early-Stage Cervical Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 1317-1330.	7.0	113
282	An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. <i>Annals of Oncology</i> , 2011, 22, 1561-1570.	1.2	150
283	Total Abdominal 18F-FDG Uptake Reflects Intestinal Adenoma Burden in Apc Mutant Mice. <i>Journal of Nuclear Medicine</i> , 2011, 52, 431-436.	5.0	9
284	Gemcitabine and Epirubicin Plasma Concentration-Related Excretion in Saliva in Patients With Non-Small Cell Lung Cancer. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 364-368.	2.0	2
285	Automated mass spectrometric analysis of urinary and plasma serotonin. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 396, 2609-2616.	3.7	64
286	Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 611-617.	1.9	30
287	Automated mass spectrometric analysis of urinary free catecholamines using on-line solid phase extraction. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 1506-1512.	2.3	57
288	The analysis of longitudinal quality of life measures with informative drop-out: a pattern mixture approach. <i>Quality of Life Research</i> , 2010, 19, 137-148.	3.1	23

#	ARTICLE	IF	CITATIONS
289	Playing the DISC: Turning on TRAIL death receptor-mediated apoptosis in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2010, 1805, 123-140.	7.4	96
290	The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 116, 549-555.	1.4	43
291	<sup>89</sup> Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922. <i>Journal of Nuclear Medicine</i> , 2010, 51, 761-767.	5.0	109
292	Elevated Urinary Free and Deconjugated Catecholamines after Consumption of a Catecholamine-Rich Diet. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2851-2855.	3.6	15
293	Receptor conversion in distant breast cancer metastases. <i>Breast Cancer Research</i> , 2010, 12, R75.	5.0	189
294	<sup>89</sup> Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. <i>European Journal of Cancer</i> , 2010, 46, 678-684.	2.8	93
295	Metformin: Taking away the candy for cancer?. <i>European Journal of Cancer</i> , 2010, 46, 2369-2380.	2.8	345
296	Sexual Function in Patients with Metastatic Midgut Carcinoid Tumours. <i>Neuroendocrinology</i> , 2009, 89, 231-236.	2.5	19
297	Enhanced Antitumor Efficacy of a DR5-Specific TRAIL Variant over Recombinant Human TRAIL in a Bioluminescent Ovarian Cancer Xenograft Model. <i>Clinical Cancer Research</i> , 2009, 15, 2048-2057.	7.0	48
298	Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study. <i>Clinical Cancer Research</i> , 2009, 15, 5584-5590.	7.0	100
299	Development and Characterization of Clinical-Grade <sup>89</sup> Zr-Trastuzumab for HER2/neu ImmunoPET Imaging. <i>Journal of Nuclear Medicine</i> , 2009, 50, 974-981.	5.0	305
300	Combining Simvastatin with the Farnesyltransferase Inhibitor Tipifarnib Results in an Enhanced Cytotoxic Effect in a Subset of Primary CD34+ Acute Myeloid Leukemia Samples. <i>Clinical Cancer Research</i> , 2009, 15, 3076-3083.	7.0	31
301	Dietary Influences on Plasma and Urinary Metanephrines: Implications for Diagnosis of Catecholamine-Producing Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2841-2849.	3.6	131
302	<sup>6</sup> -[F-18]Fluoro-Dihydroxyphenylalanine Positron Emission Tomography Is Superior to Conventional Imaging with <sup>123</sup> I-Metaiodobenzylguanidine Scintigraphy, Computer Tomography, and Magnetic Resonance Imaging in Localizing Tumors Causing Catecholamine Excess. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3922-3930.	3.6	153
303	Impact of intracellular chloride concentration on cisplatin accumulation in sensitive and resistant GLC4 cells. <i>Journal of Biological Inorganic Chemistry</i> , 2009, 14, 123-132.	2.6	12
304	The Prognostic Value of TRAIL and its Death Receptors in Cervical Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 203-211.	0.8	26
305	Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 573-580.	2.5	58
306	Fas Ligand Expression in Lynch Syndrome-Associated Colorectal Tumours. <i>Pathology and Oncology Research</i> , 2009, 15, 399-406.	1.9	8

#	ARTICLE	IF	CITATIONS
307	Variability in responsiveness to lovastatin of the primitive CD34+ AML subfraction compared to normal CD34+ cells. <i>Annals of Hematology</i> , 2009, 88, 573-580.	1.8	14
308	Analyzing longitudinal data with patients in different disease states during follow-up and death as final state. <i>Statistics in Medicine</i> , 2009, 28, 3829-3843.	1.6	11
309	Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. <i>British Journal of Cancer</i> , 2009, 101, 149-159.	6.4	97
310	Plasma tryptophan, kynurenine and 3-hydroxykynurenine measurement using automated on-line solid-phase extraction HPLC-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 603-609.	2.3	91
311	Molecular imaging in neuroendocrine tumors: Molecular uptake mechanisms and clinical results. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 199-213.	4.4	135
312	Combining 6-fluoro-[18F]-dihydroxyphenylalanine and [18F]fluoro-2-deoxy-d-glucose positron emission tomography for distinction of non-carcinoid malignancies in carcinoid patients. <i>European Journal of Cancer</i> , 2009, 45, 2312-2315.	2.8	10
313	Improvements in small bowel carcinoid diagnosis and staging: 18F-DOPA PET, capsule endoscopy and double balloon enteroscopy. <i>Digestive and Liver Disease</i> , 2009, 41, e35-e38.	0.9	12
314	Cardiovascular toxicity caused by cancer treatment: strategies for early detection. <i>Lancet Oncology</i> , The, 2009, 10, 391-399.	10.7	235
315	Role of Chemokines and Their Receptors in Cancer. <i>Current Pharmaceutical Design</i> , 2009, 15, 3396-3416.	1.9	55
316	Survival-Related Profile, Pathways, and Transcription Factors in Ovarian Cancer. <i>PLoS Medicine</i> , 2009, 6, e1000024.	8.4	156
317	Serotonin rising. <i>New England Journal of Medicine</i> , 2009, 360, 2580-1; author reply 2581-2.	27.0	4
318	Urinary 5-HIAA measurement using automated on-line solid-phase extraction-high-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 868, 28-33.	2.3	40
319	The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 189-197.	2.5	97
320	A robust <i>ex vivo</i> model for evaluation of induction of apoptosis by rhTRAIL in combination with proteasome inhibitor MG132 in human premalignant cervical explants. <i>International Journal of Cancer</i> , 2008, 123, 1457-1465.	5.1	15
321	Targeting Pro-Apoptotic TRAIL Receptors Sensitizes HeLa Cervical Cancer Cells to Irradiation-Induced Apoptosis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 543-552.	0.8	22
322	Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients. <i>Bone Marrow Transplantation</i> , 2008, 42, 475-481.	2.4	7
323	The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. <i>British Journal of Cancer</i> , 2008, 99, 341-349.	6.4	78
324	Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients. <i>BMC Cancer</i> , 2008, 8, 389.	2.6	22

#	ARTICLE	IF	CITATIONS
325	Low plasma tryptophan in carcinoid patients is associated with increased urinary cortisol excretion. Psychoneuroendocrinology, 2008, 33, 1297-1301.	2.7	6
326	Targeting TRAIL death receptors. Current Opinion in Pharmacology, 2008, 8, 433-439.	3.5	36
327	The influence of endocrine treatments for breast cancer on health-related quality of life. Cancer Treatment Reviews, 2008, 34, 640-655.	7.7	63
328	Clinical Evaluation of M30 and M65 ELISA Cell Death Assays as Circulating Biomarkers in a Drug-Sensitive Tumor, Testicular Cancer. Neoplasia, 2008, 10, 1041-1048.	5.3	77
329	Improved Staging of Patients With Carcinoid and Islet Cell Tumors With <sup>18</sup> F-Dihydroxy-Phenyl-Alanine and <sup>11</sup> C-5-Hydroxy-Tryptophan Positron Emission Tomography. Journal of Clinical Oncology, 2008, 26, 1489-1495.	1.6	240
330	Risk of New Primary Nonbreast Cancers After Breast Cancer Treatment: A Dutch Population-Based Study. Journal of Clinical Oncology, 2008, 26, 1239-1246.	1.6	181
331	Myocardial Metastases of Carcinoid Visualized by <sup>18</sup> F-Dihydroxy-Phenyl-Alanine Positron Emission Tomography. Circulation, 2008, 118, 1602-1604.	1.6	17
332	Effect of interferon and 5-fluorouracil on serum VEGF levels in neuroendocrine tumours. Acta Oncologica, 2008, 47, 153-155.	1.8	1
333	Manipulation of [11C]-5-Hydroxytryptophan and 6-[18F]Fluoro-3,4-Dihydroxy-L-Phenylalanine Accumulation in Neuroendocrine Tumor Cells. Cancer Research, 2008, 68, 7183-7190.	0.9	54
334	<sup>18</sup> F-Dihydroxyphenylalanine PET in Patients with Biochemical Evidence of Medullary Thyroid Cancer: Relation to Tumor Differentiation. Journal of Nuclear Medicine, 2008, 49, 524-531.	5.0	116
335	Exploiting the Apoptotic Route for Cancer Treatment: A Single Hit Will Rarely Result in a Home Run. Journal of Clinical Oncology, 2008, 26, 5151-5153.	1.6	8
336	Immunoscintigraphy as Potential Tool in the Clinical Evaluation of HER2/neu Targeted Therapy. Current Pharmaceutical Design, 2008, 14, 3348-3362.	1.9	32
337	A New Perspective on Transcriptional System Regulation (TSR): Towards TSR Profiling. PLoS ONE, 2008, 3, e1656.	2.5	11
338	Prospective Study of Long-Term Impact of Adjuvant High-Dose and Conventional-Dose Chemotherapy on Health-Related Quality of Life. Journal of Clinical Oncology, 2007, 25, 5403-5409.	1.6	26
339	Serum HER2 levels are increased in patients with chronic heart failure. European Journal of Heart Failure, 2007, 9, 173-177.	7.1	51
340	Translating Pharmacogenomics: Challenges on the Road to the Clinic. PLoS Medicine, 2007, 4, e209.	8.4	174
341	Cardiotoxicity associated with the use of trastuzumab in breast cancer patients. Expert Review of Anticancer Therapy, 2007, 7, 1763-1771.	2.4	28
342	Profiling Studies in Ovarian Cancer: A Review. Oncologist, 2007, 12, 960-966.	3.7	63

#	ARTICLE	IF	CITATIONS
343	Beware of Amenorrhea During Tamoxifen: It May Be a Wolf in Sheep's Clothing. <i>Journal of Clinical Oncology</i> , 2007, 25, 3787-3788.	1.6	11
344	Plasma Free Metanephrine Measurement Using Automated Online Solid-Phase Extraction HPLCâ€“Tandem Mass Spectrometry. <i>Clinical Chemistry</i> , 2007, 53, 1684-1693.	3.2	132
345	Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications. <i>Oncologist</i> , 2007, 12, 1379-1389.	3.7	304
346	Evidence Based Selection of Housekeeping Genes. <i>PLoS ONE</i> , 2007, 2, e898.	2.5	617
347	Cigarette smoke extract affects functional activity of MRP1 in bronchial epithelial cells. <i>Journal of Biochemical and Molecular Toxicology</i> , 2007, 21, 243-251.	3.0	43
348	ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 62, 214-226.	4.4	85
349	Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. <i>Lancet Oncology</i> , The, 2006, 7, 728-734.	10.7	234
350	The Prognostic Effect of the Number of Histologically Examined Axillary Lymph Nodes in Breast Cancer: Stage Migration or Age Association?. <i>Annals of Surgical Oncology</i> , 2006, 13, 465-474.	1.5	39
351	Diminished expression of multidrug resistance-associated protein 1 (MRP1) in bronchial epithelium of COPD patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 449, 682-688.	2.8	57
352	Hot flushes in breast cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 57, 63-77.	4.4	64
353	Selective expression of cholesterol metabolism genes in normal CD34+CD38â€“ cells with a heterogeneous expression pattern in AML cells. <i>Experimental Hematology</i> , 2006, 34, 622-630.	0.4	32
354	Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. <i>International Journal of Cancer</i> , 2006, 118, 1892-1900.	5.1	52
355	Circulating apoptotic proteins are increased in long-term disease-free breast cancer survivors. <i>Acta Oncologica</i> , 2006, 45, 175-183.	1.8	19
356	TRAIL Induces Apoptosis in Human Colorectal Adenoma Cell Lines and Human Colorectal Adenomas. <i>Clinical Cancer Research</i> , 2006, 12, 4350-4356.	7.0	27
357	Tumor Necrosis Factorâ€“Related Apoptosis-Inducing Ligand Pathway and Its Therapeutic Implications. <i>Clinical Cancer Research</i> , 2006, 12, 2390-2393.	7.0	56
358	Phase I Trial with BMS-275183, a Novel Oral Taxane with Promising Antitumor Activity. <i>Clinical Cancer Research</i> , 2006, 12, 1760-1767.	7.0	22
359	Indium-111â€“Labeled Trastuzumab Scintigraphy in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 2276-2282.	1.6	270
360	The relation between soluble apoptotic proteins and subclinical cardiotoxicity in adjuvant-treated breast cancer patients. <i>Anticancer Research</i> , 2006, 26, 3803-11.	1.1	5



#	ARTICLE	IF	CITATIONS
361	Irritability Rather Than Depression During Interferon Treatment Is Linked to Increased Tryptophan Catabolism. <i>Psychosomatic Medicine</i> , 2005, 67, 773-777.	2.0	45
362	A Simple and Sensitive Fully Validated HPLC-UV Method for the Determination of 5-Fluorouracil and Its Metabolite 5,6-Dihydrofluorouracil in Plasma. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 25-30.	2.0	36
363	The dilemma of the strive for apoptosis in oncology: mind the heart. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 53, 101-113.	4.4	10
364	Automated On-Line Solid-Phase Extraction Coupled with HPLC for Measurement of 5-Hydroxyindole-3-acetic Acid in Urine. <i>Clinical Chemistry</i> , 2005, 51, 1698-1703.	3.2	31
365	New positron emission tomography tracer [ <sup>11</sup> C]carvedilol reveals P-glycoprotein modulation kinetics. <i>British Journal of Pharmacology</i> , 2005, 145, 1045-1051.	5.4	46
366	Sensitivity to Fas-mediated apoptosis in high-risk HPV-positive human cervical cancer cells: Relationship with Fas, caspase-8, and Bid. <i>Gynecologic Oncology</i> , 2005, 97, 353-364.	1.4	38
367	Colorectal cancer and the CHEK2 1100delC mutation. <i>Genes Chromosomes and Cancer</i> , 2005, 43, 377-382.	2.8	27
368	Abdominal Angina in Patients with a Midgut Carcinoid, a Sign of Severe Pathology. <i>World Journal of Surgery</i> , 2005, 29, 1139-1142.	1.6	14
369	Methylenetetrahydrofolate reductase (MTHFR) and susceptibility for (pre)neoplastic cervical disease. <i>Human Genetics</i> , 2005, 116, 247-254.	3.8	36
370	The Human Leukocyte Antigen Region and Colorectal Cancer Risk. <i>Diseases of the Colon and Rectum</i> , 2005, 48, 303-306.	1.3	7
371	Preoperative Serum Squamous Cell Carcinoma Antigen Levels in Clinical Decision Making for Patients With Early-Stage Cervical Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 1455-1462.	1.6	57
372	Expression of Multidrug Resistance-Associated Proteins Predicts Prognosis in Childhood and Adult Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2005, 11, 8661-8668.	7.0	103
373	Fatigue and Relating Factors in High-Risk Breast Cancer Patients Treated With Adjuvant Standard or High-Dose Chemotherapy: A Longitudinal Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 8296-8304.	1.6	86
374	Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Thrombospondin-1-Mimetic Angiogenesis Inhibitor ABT-510 in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 5188-5197.	1.6	96
375	Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: changing the apoptotic balance. <i>Lancet Oncology</i> , The, 2005, 6, 589-598.	10.7	40
376	Testicular germ cell tumours: The paradigm of chemo-sensitive solid tumours. <i>International Journal of Biochemistry and Cell Biology</i> , 2005, 37, 2437-2456.	2.8	53
377	Predicting Early Failure after Adjuvant Chemotherapy in High-Risk Breast Cancer Patients with Extensive Lymph Node Involvement. <i>Clinical Cancer Research</i> , 2004, 10, 4457-4463.	7.0	39
378	Complications of Midgut Carcinoid Tumors and Carcinoid Syndrome. <i>Neuroendocrinology</i> , 2004, 80, 28-32.	2.5	42



#	ARTICLE	IF	CITATIONS
379	Low p21Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis. <i>Oncogene</i> , 2004, 23, 4862-4872.	5.9	39
380	Preclinical characterisation of 111 In-DTPA-trastuzumab. <i>British Journal of Pharmacology</i> , 2004, 143, 99-106.	5.4	140
381	No association between two MLH3 variants (S845G and P844L) and colorectal cancer risk. <i>Cancer Genetics and Cytogenetics</i> , 2004, 152, 70-71.	1.0	15
382	Quality of adjuvant CMF chemotherapy for node-positive primary breast cancer: a population-based study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2004, 130, 581-590.	2.5	7
383	Diagnostic $^{131}$ scintigraphy in patients with differentiated thyroid cancer: No additional value of higher scan dose. <i>Annals of Nuclear Medicine</i> , 2004, 18, 641-6.	2.2	9
384	In vivo imaging of hepatobiliary transport function mediated by multidrug resistance associated protein and P-glycoprotein. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 131-138.	2.3	58
385	Elevated hTERT mRNA levels: A potential determinant of bronchial squamous cell carcinoma (<i>in Tj ETQq1 1 0.784314 rgBT <sub>21</sub> /Overlook	5.1	21
386	Influence of functional polymorphisms of the gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 220-229.	4.7	77
387	Breast Cancer Resistance Protein (BCRP) in Acute Leukaemia. <i>Leukemia and Lymphoma</i> , 2004, 45, 649-654.	1.3	35
388	Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. <i>Drug Resistance Updates</i> , 2004, 7, 345-358.	14.4	146
389	Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation?. <i>Cancer Treatment Reviews</i> , 2004, 30, 37-51.	7.7	64
390	ENDOTOXIN INCREASES PLASMA SOLUBLE TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND LEVEL MEDIATED BY THE p38 MITOGEN-ACTIVATED PROTEIN KINASE SIGNALING PATHWAY. <i>Shock</i> , 2004, 22, 186-188.	2.1	23
391	Experimental animal model for anthracycline-induced heart failure. <i>European Journal of Heart Failure</i> , 2004, 6, 375-376.	7.1	1
392	Patients With Carcinoid Syndrome Exhibit Symptoms of Aggressive Impulse Dysregulation. <i>Psychosomatic Medicine</i> , 2004, 66, 422-425.	2.0	32
393	Extensive hepatic replacement due to liver metastases has no effect on 5-fluorouracil pharmacokinetics. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 51, 167-173.	2.3	9
394	Pilot study of vaginal plethysmography in women treated with radiotherapy for gynecological cancer. <i>Gynecologic Oncology</i> , 2003, 91, 540-546.	1.4	16
395	Detection of micrometastatic breast cancer by means of real time quantitative RT-PCR and immunostaining in perioperative blood samples and sentinel nodes. <i>International Journal of Cancer</i> , 2003, 106, 611-618.	5.1	41
396	Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. <i>Journal of Pathology</i> , 2003, 200, 327-335.	4.5	118

#	ARTICLE	IF	CITATIONS
397	The attractive Achilles heel of germ cell tumours: an inherent sensitivity to apoptosis-inducing stimuli. <i>Journal of Pathology</i> , 2003, 200, 137-148.	4.5	71
398	High Functional P-glycoprotein Activity is More Often Present in T-cell Acute Lymphoblastic Leukaemic Cells in Adults than in Children. <i>Leukemia and Lymphoma</i> , 2003, 44, 85-95.	1.3	38
399	Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [ <sup>11</sup> C]verapamil measured with PET. <i>NeuroImage</i> , 2003, 20, 1775-1782.	4.2	80
400	Intraperitoneal chemotherapy for ovarian cancer: a question of feasibility?. <i>Drug Resistance Updates</i> , 2003, 6, 165-167.	14.4	5
401	The HLA class III subregion is responsible for an increased breast cancer risk. <i>Human Molecular Genetics</i> , 2003, 12, 2311-2319.	2.9	37
402	Catecholamine-Synthesizing Enzymes in Carcinoid Tumors and Pheochromocytomas. <i>Clinical Chemistry</i> , 2003, 49, 586-593.	3.2	52
403	Toward New Strategies to Select Young Endometrial Cancer Patients for Mismatch Repair Gene Mutation Analysis. <i>Journal of Clinical Oncology</i> , 2003, 21, 4364-4370.	1.6	120
404	High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast Cancer. <i>New England Journal of Medicine</i> , 2003, 349, 7-16.	27.0	240
405	Determination of Epirubicin and Its Metabolite Epirubicinol in Saliva and Plasma by HPLC. <i>Therapeutic Drug Monitoring</i> , 2003, 25, 433-440.	2.0	31
406	Tryptophan as a Link between Psychopathology and Somatic States. <i>Psychosomatic Medicine</i> , 2003, 65, 665-671.	2.0	93
407	Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. <i>Journal of Nuclear Medicine</i> , 2003, 44, 184-91.	5.0	60
408	Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. <i>Clinical Cancer Research</i> , 2003, 9, 3397-405.	7.0	100
409	The role of breast cancer resistance protein in acute lymphoblastic leukemia. <i>Clinical Cancer Research</i> , 2003, 9, 5171-7.	7.0	43
410	Better Yield of <sup>18</sup> F-Fluorodeoxyglucose-Positron Emission Tomography in Patients with Metastatic Differentiated Thyroid Carcinoma during Thyrotropin Stimulation. <i>Thyroid</i> , 2002, 12, 381-387.	4.5	81
411	Calcium or Resistant Starch Does Not Affect Colonic Epithelial Cell Proliferation Throughout the Colon in Adenoma Patients: A Randomized Controlled Trial. <i>Nutrition and Cancer</i> , 2002, 43, 31-38.	2.0	17
412	Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. <i>Blood</i> , 2002, 99, 3763-3770.	1.4	116
413	The Role of Apoptosis-Related Genes in non-small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2002, 4, 174-182.	2.6	7
414	Molecular and Clinical Characteristics of MSH6 Variants: An Analysis of 25 Index Carriers of a Germline Variant. <i>American Journal of Human Genetics</i> , 2002, 70, 26-37.	6.2	271

#	ARTICLE	IF	CITATIONS
415	An oncological view on the bloodâ€testis barrier. <i>Lancet Oncology</i> , The, 2002, 3, 357-363.	10.7	158
416	Phase I and Pharmacologic Study of Liposomal Lurtotecan, NX 211: Urinary Excretion Predicts Hematologic Toxicity. <i>Journal of Clinical Oncology</i> , 2002, 20, 1222-1231.	1.6	39
417	JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin. <i>Biochemical Pharmacology</i> , 2002, 63, 1989-1996.	4.4	64
418	S-Decyl-glutathione nonspecifically stimulates the ATPase activity of the nucleotide-binding domains of the human multidrug resistance-associated protein, MRP1 (ABCC1). <i>FEBS Journal</i> , 2002, 269, 3470-3478.	0.2	7
419	Fas receptor-mediated apoptosis: a clinical application?. <i>Journal of Pathology</i> , 2002, 196, 125-134.	4.5	118
420	Metastasis in soft tissue sarcomas: prognostic criteria and treatment perspectives. <i>Cancer and Metastasis Reviews</i> , 2002, 21, 167-183.	5.9	42
421	Profiling of Tryptophan-related Plasma Indoles in Patients with Carcinoid Tumors by Automated, On-Line, Solid-Phase Extraction and HPLC with Fluorescence Detection. <i>Clinical Chemistry</i> , 2001, 47, 1811-1820.	3.2	86
422	TAMOXIFEN TREATMENT AND GYNECOLOGIC SIDE EFFECTS. <i>Obstetrics and Gynecology</i> , 2001, 97, 855-866.	2.4	69
423	Routine bone scintigraphy in primary staging of soft tissue sarcoma. <i>Cancer</i> , 2000, 89, 1726-1731.	4.1	33
424	One year growth hormone replacement therapy does not alter colonic epithelial cell proliferation in growth hormone deficient adults. <i>Clinical Endocrinology</i> , 2000, 52, 457-462.	2.4	21
425	Discriminating Capacity of Indole Markers in the Diagnosis of Carcinoid Tumors. <i>Clinical Chemistry</i> , 2000, 46, 1588-1596.	3.2	120
426	The (patho)physiological functions of the MRP family. <i>Drug Resistance Updates</i> , 2000, 3, 289-302.	14.4	91
427	ATPâ€and glutathioneâ€dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. <i>British Journal of Pharmacology</i> , 1999, 126, 681-688.	5.4	224
428	Differential regulation of IL-6 promoter activity in a human ovarian-tumor cell line transfected with various p53 mutants: Involvement of AP-1. , 1999, 81, 236-242.		25
429	Telomerase targeting in cancer treatment: new developments. <i>Drug Resistance Updates</i> , 1999, 2, 104-115.	14.4	16
430	Comparison of the kinetics of active efflux of <sup>99m</sup> Tc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes. <i>FEBS Journal</i> , 1998, 252, 140-146.	0.2	51
431	Clinical relevance of transforming growth factor $\beta$ , epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. <i>Hepatology</i> , 1998, 28, 971-979.	7.3	112
432	Transport of glutathione conjugates into secretory vesicles is mediated by the multidrug-resistance protein 1. , 1998, 76, 55-62.		56

#	ARTICLE	IF	CITATIONS
433	Differential effects of all-trans -retinoic acid, docosahexaenoic acid, and hexadecylphosphocholine on cisplatin-induced cytotoxicity and apoptosis in a cisplatin-sensitive and resistant human embryonal carcinoma cell line. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 41, 469-476.	2.3	37
434	Renal toxicity of the anticancer drug fostriecin. <i>Cancer Chemotherapy and Pharmacology</i> , 1998, 42, 160-164.	2.3	11
435	Heat-shock protein expression in cisplatin-sensitive and -resistant human tumor cells. , 1996, 67, 800-807.		36
436	Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts. <i>Cancer</i> , 1995, 75, 1004-1009.	4.1	41
437	5-fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration. <i>Cancer</i> , 1995, 75, 1072-1076.	4.1	6
438	Sensitization to cisplatin action by step-down heating in cddp-sensitive and -resistant cells. <i>International Journal of Cancer</i> , 1995, 61, 722-726.	5.1	12
439	The role of methoxymorpholino anthracycline and cyanomorpholino anthracycline in a sensitive small-cell lung-cancer cell line and its multidrug-resistant but P-glycoprotein-negative and cisplatin-resistant counterparts. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 35, 345-348.	2.3	0
440	Tumor progression in a giant cell type malignant fibrous histiocytoma of bone: Clinical, radiologic, histologic, and cytogenetic evidence. <i>Genes Chromosomes and Cancer</i> , 1994, 10, 66-70.	2.8	10
441	Effect of ultrafilterable platinum concentration on cisplatin and carboplatin cytotoxicity in human tumor and bone marrow cells in vitro. <i>Pharmaceutical Research</i> , 1994, 11, 1265-1269.	3.5	3
442	Effect of novobiocin on cisplatin cytotoxicity and dna interstrand cross-link formation in a cisplatin-resistant, small-cell lung carcinoma cell line. <i>International Journal of Cancer</i> , 1993, 53, 110-117.	5.1	16
443	Evaluation of S9788 as a potential modulator of drug resistance against human tumour sublines expressing differing resistance mechanisms In Vitro. <i>International Journal of Cancer</i> , 1993, 55, 330-337.	5.1	10
444	HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients. <i>Cancer Immunology, Immunotherapy</i> , 1993, 36, 198-204.	4.2	15
445	Stability of the new anticancer platinum analogue 1,2-diaminomethyl-cyclobutane-platinum(II)-lactate (lobaplatin; D19466) in intravenous solutions. <i>Pharmaceutical Research</i> , 1992, 09, 808-811.	3.5	10
446	Successful long-term control of idiopathic hypereosinophilic syndrome with etoposide. <i>Cancer</i> , 1991, 67, 2826-2827.	4.1	65
447	Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 461-464.	2.3	29
448	A phase II study of carboplatin and vincristine in previously treated patients with small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 25, 202-204.	2.3	12
449	Continuous infusion of low-dose doxorubicin, epirubicin and mitoxantrone in cancer chemotherapy: A review. <i>Pharmaceutisch Weekblad</i> , 1988, 10, 237-245.	0.7	9
450	Renal dysfunction following high-dose carboplatin treatment. <i>Journal of Cancer Research and Clinical Oncology</i> , 1988, 114, 212-214.	2.5	17

#	ARTICLE	IF	CITATIONS
451	A patient education program for a continuous infusion regimen on an outpatient basis. Cancer Nursing, 1987, 10, 177-182.	1.5	12
452	TNO-6-induced acute renal failure. A case report. Cancer, 1985, 56, 1511-1514.	4.1	5